Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSRPT
āļāļ·āđāļāļāļĢāļīāļĐāļąāļSarepta Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 04, 1997
āļāļĩāļāļĩāđāļIngram (Douglas S)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ1372
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJun 04
āļāļĩāđāļāļĒāļđāđ215 First Street
āđāļĄāļ·āļāļCAMBRIDGE
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02142
āđāļāļĢāļĻāļąāļāļāđ16172744000
āđāļ§āđāļāđāļāļāđhttps://www.sarepta.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļSRPT
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJun 04, 1997
āļāļĩāļāļĩāđāļIngram (Douglas S)
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
Ms. Cristin L. Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
Ms. Deirdre Connelly
Independent Director
Dr. Claude Nicaise, M.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
President - Research and Development and Technical Operations
President - Research and Development and Technical Operations
Mr. Ian Michael Estepan
President, Chief Operating Officer
President, Chief Operating Officer
Mr. Ryan Wong
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
iShares Neuroscience and Healthcare ETF
First Trust NYSE Arca Biotechnology Index Fund
Invesco Biotechnology & Genome ETF
Invesco S&P SmallCap Health Care ETF
Global X Genomics & Biotechnology ETF
Invesco S&P SmallCap 600 Pure Growth ETF
Virtus LifeSci Biotech Products ETF
State Street SPDR S&P Biotech ETF
Direxion Daily S&P Biotech Bull 3X Shares
First Trust Health Care Alphadex Fund
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
iShares Neuroscience and Healthcare ETF
āļŠāļąāļāļŠāđāļ§āļ3.74%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļāļŠāđāļ§āļ3.65%
Invesco Biotechnology & Genome ETF
āļŠāļąāļāļŠāđāļ§āļ3.49%
Invesco S&P SmallCap Health Care ETF
āļŠāļąāļāļŠāđāļ§āļ1.44%
Global X Genomics & Biotechnology ETF
āļŠāļąāļāļŠāđāļ§āļ1.39%
Invesco S&P SmallCap 600 Pure Growth ETF
āļŠāļąāļāļŠāđāļ§āļ1.32%
Virtus LifeSci Biotech Products ETF
āļŠāļąāļāļŠāđāļ§āļ1.03%
State Street SPDR S&P Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ1.03%
Direxion Daily S&P Biotech Bull 3X Shares
āļŠāļąāļāļŠāđāļ§āļ0.63%
First Trust Health Care Alphadex Fund
āļŠāļąāļāļŠāđāļ§āļ0.51%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ